Milne RJ - Search Results

1

Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk.

Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Jackson R, et al. Among authors: milne rj. Lancet. 2005 Jan 29-Feb 4;365(9457):434-41. doi: 10.1016/S0140-6736(05)17833-7. Lancet. 2005. PMID: 15680460

2

A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.

Milne RJ, Vander Hoorn S, Jackson RT. Milne RJ, et al. Pharmacoeconomics. 1997 Sep;12(3):384-408. doi: 10.2165/00019053-199712030-00010. Pharmacoeconomics. 1997. PMID: 10170463

3

IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care.

Selak V, Elley CR, Crengle S, Harwood M, Doughty R, Arroll B, Bryant L, Rafter N, Hoorn SV, Wadham A, Wells S, Milne R, Jackson R, Bramley D, Rodgers A. Selak V, et al. Contemp Clin Trials. 2011 Nov;32(6):909-15. doi: 10.1016/j.cct.2011.07.006. Epub 2011 Jul 18. Contemp Clin Trials. 2011. PMID: 21777702 Clinical Trial.

4

Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.

Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, Parag V, Harwood M, Doughty RN, Arroll B, Milne RJ, Bramley D, Bryant L, Jackson R, Rodgers A. Selak V, et al. Among authors: milne rj. BMJ. 2014 May 27;348:g3318. doi: 10.1136/bmj.g3318. BMJ. 2014. PMID: 24868083 Free article. Clinical Trial.

5

Quantifying the effect of age on short-term and long-term case fatality in 14,000 patients with incident cases of cardiovascular disease.

Marshall RJ, Milne RJ, Lynn R, Jackson R. Marshall RJ, et al. Among authors: milne rj. Eur J Cardiovasc Prev Rehabil. 2008 Apr;15(2):179-84. doi: 10.1097/HJR.0b013e3282f14a7f. Eur J Cardiovasc Prev Rehabil. 2008. PMID: 18391645

6

Reimbursement of pharmaceuticals in New Zealand: comments on PHARMAC's processes.

Swinburn B, Milne RJ, Richards M, Begg E, Foote S, Jackson R. Swinburn B, et al. Among authors: milne rj. N Z Med J. 2000 Oct 13;113(1119):425-8. N Z Med J. 2000. PMID: 11127362 No abstract available.

7

Framingham Heart Study risk equation predicts first cardiovascular event rates in New Zealanders at the population level.

Milne R, Gamble G, Whitlock G, Jackson R. Milne R, et al. N Z Med J. 2003 Nov 7;116(1185):U662. N Z Med J. 2003. PMID: 14615804

8

Discriminative ability of a risk-prediction tool derived from the Framingham Heart Study compared with single risk factors.

Milne R, Gamble G, Whitlock G, Jackson R. Milne R, et al. N Z Med J. 2003 Nov 7;116(1185):U663. N Z Med J. 2003. PMID: 14615805

9

Valuing prevention: discounting health benefits and costs in New Zealand.

Milne R. Milne R. N Z Med J. 2005 May 6;118(1214):U1443. N Z Med J. 2005. PMID: 15886738 No abstract available.

10

Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.

Chrisp P, Lewis NJ, Milne RJ. Chrisp P, et al. Among authors: milne rj. Pharmacoeconomics. 1992 Feb;1(2):124-45. doi: 10.2165/00019053-199201020-00009. Pharmacoeconomics. 1992. PMID: 10146941 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

74 results

Search Page

Filters